Global CAR-T Therapy Pipeline Analysis Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

Overview and Scope

The chimeric antigen receptor -T therapy is a type of immunotherapy in which T-cells are taken from the patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs.

Sizing and Forecast
The car-t therapy pipeline analysis market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%.  The  growth in the historic period can be attributed to increases in healthcare expenditure, increase in pharmaceutical r&d expenditure and advances in drug discovery.

The car-t therapy pipeline analysis market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%.  The growth in the forecast period can be attributed to increase in blood cancer incidence rate, rise in healthcare expenditure, strong pipeline of drugs and rising focus on car-t therapy. Major trends in the forecast period include investing in the r&d for creating remodeled car-t therapy to avoid neurological side-effects, creating off-the-shelf allogeneic car-t therapy for advanced cancer treatment, manufacturing next-generation car t cells for improved treatment of high-grade glioma, investing in ai and machine learning solutions to optimize future car-t therapy, carrying out strategic collaborations to boost innovations, collaborating or acquiring competitor companies to expand car-t therapy portfolio, and investing in the car-t therapy to make it more effective.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Segmentation & Regional Insights
The car-t therapy pipeline analysis market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens
3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications

North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy pipeline analysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6670&type=smp

Major Driver Impacting Market Growth
The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy. The government and non-government organizations provide financial support to the companies in the CAR-T therapy market for research and development and the patients for their treatment of acute lymphoblastic leukemia (ALL). For instance, in December 2021, the University of California San Diego School of Medicine (CA, USA) was granted a funding of US$ 4.1 million for the development of novel chimeric antigen receptor (CAR-T) cell therapy. The grant was awarded by California Institute for Regenerative Medicine (CIRM; CA, USA) governing board. The financial support provided by different organizations towards CAR-T therapy positively drives the growth of the CAR-T therapy market.

Key Industry Players
Major companies operating in the car-t therapy pipeline analysis market report are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd, Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline plc, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram

The car-t therapy pipeline analysis market report table of contents includes:
1. Executive Summary

2. CAR-T Therapy Market Characteristics

3. CAR-T Therapy Market Trends And Strategies

4. CAR-T Therapy Market - Macro Economic Scenario

5. Global CAR-T Therapy Market Size and Growth

.

32. Global CAR-T Therapy Market Competitive Benchmarking

33. Global CAR-T Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The CAR-T Therapy Market

35. CAR-T Therapy Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model